After axing its lead obesity asset last year, BioAge Labs has turned its attention to attacking inflammation in its pursuit ...

Interest in metabolic medicines is riding high, led by the popular class of weight management drugs known as GLP-1 agonists. BioAge Labs aims to help those medications work better with a lead drug ...

The combination of an experimental BioAge Labs drug with the approved Eli Lilly obesity medication Zepbound has hit a major setback: a safety signal observed in some clinical trial participants that ...

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

Shares of BioAge Labs (BIOA) continued to spike for the second consecutive session on Tuesday in reaction to updated results from an early-stage trial for the company’s lead asset, BGE-102, targeted ...

BioAge reports that BGE-102 has demonstrated weight loss in preclinical models both alone and in combination with GLP-1 receptor agonists. The Phase 1 single ascending dose/multiple ascending dose ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more ...

Funding to advance Phase 2 clinical trials of azelaprag, an apelin receptor (APJ) agonist, in combination with Lilly’s Zepbound (tirzepatide) and therapeutic pipeline Azelaprag improves metabolic and ...

Obesity drug developer BioAge Labs (BIOA) has filed regulatory filings as part of its U.S. IPO. It seeks to offer 7.5M shares at a price range of $17 to $19, implying a valuation of up to $602M at the ...

(Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor ...